FDA Approves Silodosin for the Treatment of Benign Prostatic Hyperplasia
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Silodosin for the Treatment of Benign Prostatic Hyperplasia

NEW YORK -- October 9, 2008 -- The US Food and Drug Administration (FDA) has approved silodosin (Rapaflo) for the treatment of benign prostatic hyperplasia (BPH) symptoms.

The approval is based on data from 2 randomised, double-blind, placebo-controlled, phase 3 trials lasting 12 weeks, and one 40-week open label study. In the 2 phase 3 studies, 923 patients (mean age 64.6 years) were randomised to receive either silodosin 8 mg QD or placebo.

Results from both trials showed that silodosin 8 mg QD for 12 weeks resulted in significant and rapid relief of BPH symptoms, compared with placebo, as measured by the International Prostate Symptom Score (IPSS). IPSS includes irritative and obstructive symptoms.

The most common drug-related side effect was retrograde ejaculation. Rates of discontinuing therapy due to retrograde ejaculation were low. The second most commonly-reported adverse event was dizziness. The incidence of treatment-related dizziness was low and only slightly higher in patients receiving silodosin compared with placebo-treated patients.

SOURCE Watson Pharmaceuticals, Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities